Organ Chips Replace Animal Testing: FDA New Rule Transforms Pharmaceutical Industry

On December 10, the U.S. Food and Drug Administration (FDA) issued a final rule formally allowing pharmaceutical companies to use organ-on-a-chip data in place of certain animal experiments in new drug applications (IND/NDA). Dubbed a "milestone" by the industry, the new rule is expected to reduce drug development timelines by 30% and costs by 40%.

Organ-on-a-chip is a microfluidic device that mimics the structure and function of human organs on a chip. A stamp-sized chip integrates living cells, vascular channels, and sensors to simulate drug metabolism in the human body.

Emulate Bio, the industry leader, offers a "Human Emulation" platform comprising 12 organ chips — liver, kidney, lung, intestine, brain, and more — that can be linked to simulate a complete physiological system. "Animal experiments have a prediction accuracy of only about 50%. Organ chips achieve over 87% human prediction accuracy," said CEO Jim Corbett.

The FDA's new rule lists 7 categories where organ chip data can replace animal experiments, including acute toxicity assessment, skin sensitization testing, and drug metabolism studies. However, chronic toxicity and carcinogenicity testing still require animal experiment data.

China's National Medical Products Administration (NMPA) is also closely monitoring this trend. Reports indicate the NMPA is drafting similar guidelines, with a public comment period expected in the first half of 2028.

Ethical organizations welcomed the progress but noted that "reducing animal experiments" does not mean "eliminating animal experiments," urging regulators to set clearer timelines.